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Abstract
Background: Studies have found admission hyperglycemia as a predictor of poor outcomes in
Community acquired Pneumonia (CAP), whereas others have not. The objective of this study was
to evaluate the impact of diabetes mellitus (DM) on mortality as well as Length of stay (LOS) and
Time to clinical stability (TCS) of hospitalized patients with CAP.
Materials and Methods: Adult patients hospitalized with CAP enrolled at Community-Acquired
Pneumonia Organization (CAPO) database with DM were categorized as admission blood glucose ≥ 250 mg/dL (diabetes mellitus blood sugar (BG) > 250) and admission blood glucose ≤
250 mg/dL (DM BG ≤ 250). CAP outcomes included: all-cause in-hospital mortality, all-cause
28-day mortality, length of stay (LOS) and time to clinical stability (TCS).
Results: From a total of 7,303 patients with CAP, 294 (17.7%) had DM; out of whom 960 (13.1%)
patients had BG ≤ 250 mg/dL, and 334 (4.6%) patients had BG > 250 mg/dL. The in-hospital
mortality was 9.3% for controls, 9.9% for the DM BG ≤ 250 mg/dL group and 13.4% for DM BG
> 250 mg/dL group (p=0.04). Patients with DM BG > 250 mg/dL compared to the control group
had a higher risk of in-hospital mortality (Hazard ratio (RR) = 1.32, 95% CI: 1.02-1.72, p = 0.034)
and 28-day mortality (RR = 1.31, 95% CI: 1.01-1.71, p = 0.048). Patients in the DM BG ≤ 250
mg/dL group compared to the control group did not have a greater risk for in-hospital mortality
(RR = 1.23, 95% CI: 0.16-8.09, p = 0.237), 28-day mortality (RR = 1.09, 95% CI: 0.90-1.32, p =
0.398), LOS (HR = 0.93, 95% CI: 0.85-1.02, p = 0.130), or TCS (HR = 0.95, 95% CI: 0.87-1.05, p
= 0.320).
Conclusions: DM patients with BG > 250 mg/dL were associated with increased in-hospital
mortality and 28-day mortality. Further studies are needed to link the role of hyperglycemia to
CAP outcome.

1

Background

Diabetes mellitus (DM) is among the most common chronic diseases worldwide, accounting for an enormous strain on healthcare resources, increased morbidity and mortality, and decreased
quality of life 1 . High rates of infectious complications and poor
response to infections such as community acquired pneumonia
(CAP) are often reported among patients with DM 2,3 . Establishing clear relationships between DM and mortality in CAP are also
confounded by comorbidities in this population including cerebrovascular events, cardiovascular disease, and kidney disease,
all of which negatively impact clinical outcomes in CAP 4 .
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Studies have reported inconsistent results regarding the impact
of DM on clinical outcomes of patients with CAP. Several investigations have shown increased CAP mortality among patients with
DM compared to patients without DM 5–7 , whereas others found
no association 1 . Similarly, some studies have found admission hyperglycemia as a predictor of poor outcomes in CAP 8,9 , whereas
others have not 10 . There are also other important outcomes measures in CAP patients like length of hospital stay (LOS) and Time
to Clinical Stability (TCS) that have been shown to predict inpatient as well as post-discharge adverse outcomes in CAP 11 . Very
few studies examined these outcomes in patients with DM and
CAP 11 .
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The objective of this study was to evaluate the impact of DM on
mortality as well as LOS and TCS of hospitalized patients with
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23–28 | 23

CAP from the data obtained from the Community-Acquired Pneumonia Organization (CAPO) database.
The objective of the study is to compare outcome of community
acquired pneumonia in diabetic population in comparison with
non-diabetic population. In addition, we will compare the outcomes between the non-diabetic population (Control group) with
diabetic group with Blood glucose of more than or equal to 250
and also look at the association between the control group with
diabetic group with Blood glucose less than 250.

2
2.1

Materials and Methods
Study Design

This was a retrospective observational study of adult patients hospitalized with CAP from 40 hospitals in 13 countries. Data were
collected from patients admitted from June 2001 to June 2006
by members of the Community-Acquired Pneumonia Organization (CAPO). The local institutional review boards at each hospital approved the study. Non-consecutive medical records of hospitalized patients with a clinical diagnosis of CAP were randomly
selected for review at each of the participating hospitals. Data
collected included information on comorbidities, laboratory data,
radiographic findings, clinical findings upon admission, and clinical outcomes as indicated in the study definition. For each case, a
clinical investigator completed and submitted a case report form
electronically to the database at the CAPO study center at the University of Louisville (Kentucky, U.S.A.). Validation of data quality
was performed by a group of investigators before cases were entered into the database. Details and objectives of CAPO have been
published 12 .
2.2

Study Definitions

CAP was defined as the presence of a new pulmonary infiltrate
on a chest radiograph at the time of hospitalization that was associated with at least one of the following: 1) new or increased
cough; 2) an abnormal temperature (< 35.6◦ C or > 37.8◦ C);
3) an abnormal blood cell count (WBC), which is considered to
be present if the patient had WBC > 10.500 cells/µL, leukopenia (WBC) < 4.500 cells/µL, or left shift (> 5% immature neutrophils). Additionally, pneumonia was considered community
acquired if a patient had no previous history of hospitalization
within the 90 days prior to admission. DM was defined as a
previously diagnosed by a physician; a prescription of insulin or
oral anti-hyperglycemic drug, or random plasma glucose of > 250
mg/dL on admission. Although the cutoff for undiagnosed DM is
200 mg/dL, the 250 mg/dL cut-off in this study was chosen only
because the data for blood glucose values were collected according to the CAPO protocol following the Pneumonia Severity Index
(PSI). In our study, patients with DM were categorized into two
groups: one group with blood glucose > 250 mg/dL (DM BG >
250) and other group with blood glucose ≤ 250 mg/dL (DM BG
≤ 250). The control group includes population with no prior DM
diagnosis in medical records and no prescription of insulin/oral
anti-hyperglycemic drugs and with the plasma glucose of ≤ 250
mg/dL at the time of admission. Four outcome measures were
examined for this study: all-cause in-hospital mortality, all-cause
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28-day mortality, LOS from admission to discharge or expiration,
and Time to Clinical stability. The time to clinical stability was calculated as the number of days from the date of hospital admission
to the date that patient met clinical stability criteria. Clinical stability was defined as follows: improved clinical signs (improved
cough and shortness of breath), lack of fever for at least 24 hours,
improving leukocytosis (decreased at least 10% from the previous
day), and tolerating oral intake 13 .
2.2.1

Statistical Analysis

Baseline patient characteristics between the control group, DM
≤ 250 mg/dL and DM > 250 mg/dL were compared using chisquared tests for categorical variables and the Mann-Whitney Utest for continuous variables. To examine the effects of DM ≤ 250
mg/dL and DM > 250 mg/dL on in-hospital mortality, 28-day
mortality, LOS and TCS, a backward selection logistic regression
model was constructed, including each group as dummy variables
with the control group as the reference group. To control for confounding in the evaluation of the effect of diabetes status on each
of the four outcomes (in-hospital mortality, 28-day mortality, TCS
and LOS), multivariable regression models were used: Poisson
regression with robust error variance estimates for dichotomous
outcomes and Cox proportional hazards for time to event outcomes. Variable selections for the models were chosen via a twostep process. First, generalized linear models were constructed
for each outcome, separately. Each model included all potential
candidate confounders listed in Table 1. Variables with a p-value
of ≤ 0.10 were included in a second regression model that selected the most parsimonious best fitting model using a genetic
algorithm based on sample-size corrected Akaike information criteria. This allowed a different set of candidate confounding variables to be selected for each outcome. The variables remaining in
this best fit model were included in a final regression model.

3

Results

A total of 7,303 patients with CAP were examined in this study.
DM was identified in 1,294 (17.7%) patients, out of whom 960
(13.1%) patients had BG ≤ 250 mg/dL, and 334 (4.6%) patients
had BG > 250 mg/dL. Patient demographics, comorbidities, clinical characteristics, and laboratory results are shown in Table 1.
Study participants with DM were more commonly male, older,
had greater comorbidities, and had a higher PSI score. The Primary outcomes used in this study are in-hospital mortality, 28
days mortality, Length of stay (LOS) and time to clinical stability.
The unadjusted rate of the measured outcomes in different groups
is presented in Figure 1. The only significant finding was found
for in-hospital mortality which showed a significant increasing
trend from 9.3% in the control group to 9.9% and 13.4% respectively in the DM BG ≤ 250 mg/dL and DM BG > 250 mg/dL
(p=0.04) The univariate and multivariate logistic regression results of the impact of DM on the clinical outcomes of hospitalized
patients with CAP are shown in Table 2. Patients with DM BG >
250 mg/dL compared to the control group had a statistically significant higher risk of in-hospital mortality (Relative Ratio (RR) =
1.32, 95% CI: 1.02-1.72, p = 0.034) and 28-day mortality (Relative Ratio (RR) = 1.31, 95% CI: 1.01-1.71, p = 0.048). However,

(a) In hospital mortality

(b) 28-day mortality

(c) Length of stay

(d) Time to clinical stability

Fig. 1 Unadjusted crude rate of the measured outcomes in the control and diabetes groups
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Table 1 Characteristics of control group (no DM), patients with DM blood glucose > 250 mg/dL

Variable

Control group
DM BG≤250
DM BG>250
P-Value
n=6009 n (%)
n=960 n (%)
n=334 n (%)
Demographics
Age, Median (IQR)
68 (32)
71 (19)
70 (21)
<.0001
Male Gender
3562 (59.3)
642 (66.9)
205 (61.4)
<0.001
Comorbid Conditions
COPD
1491 (24.8)
289 (30.1)
70 (21.0)
<0.001
Liver Disease
331 (5.5)
53 (5.5)
18 (5.4)
0.955
Renal Disease
518 (8.6)
179 (18.6)
42 (12.6)
<0.001
Neoplastic Disease
604 (10.1)
109 (11.4)
29 (8.7)
0.305
Congestive Heart Failure
951 (15.8)
251 (26.1)
90 (26.9)
<0.001
Cerebrovascular Accident
806 (13.4)
162 (16.9)
68 (20.4)
<0.001
Laboratory and Physical Findings
PaO2 <60mm Hg
1917 (31.9)
307 (32.0)
126 (37.7)
0.085
Hematocrit <30%
437 (7.3)
92 (9.6)
25 (7.5)
0.043
Blood Urea Nitrogen ≥30 mg/dl
1647 (27.4)
316 (32.9)
119 (35.6)
<0.001
pH 7.35
328 (5.5)
60 (6.2)
30 (9.0)
0.02
Sodium <130 mmol/liter
394 (6.6)
63 (6.6)
49 (14.7)
<0.001
◦
◦
Temperature <35 C or ≥40 C
419 (7.0)
62 (6.5)
29 (8.7)
0.388
Systolic Blood Pressure <90mm Hg
349 (5.8)
39 (4.1)
14 (4.2)
0.05
Heart Rate ≥125 beats /min
771 (12.8)
88 (9.2)
55 (16.5)
0.001
Respiratory Rate >30 breaths/min
1163 (19.4)
139 (14.5)
71 (21.3)
0.001
Severity of Disease
Need for Intensive Care
840 (14.0)
125 (13.0)
61 (18.3)
0.056
Multilobar Infiltrates
1646 (27.4)
281 (29.3)
83 (24.9)
0.257
Pleural Effusion
1274 (21.2)
210 (21.9)
81 (24.3)
0.391
Altered Mental Status
863 (14.4)
146 (15.2)
59 (17.7)
0.216
Pneumonia Severity Index, Median (IQR)
92 (54)
101.5 (45.25)
115 (54)
<0.001
Quality of Care and Prevention
Blood Cultures Obtained
4181 (69.6)
707 (73.6)
234 (70.1)
0.038
History of Pneumococcal Vaccine
842 (15.7)
189 (19.7)
71 (21.3)
<0.001
History of Influenza Vaccine
850 (17.0)
170 (21.7)
68 (23.0)
<0.001
Note: Reference group is non-DM patients with blood glucose level ≤ 250 mg/dL (control group)

Table 2 Adjusted results by multivariate logistic regression model

Risk Ratio (95% CI)
p-value
Blood Glucose (mg/dL)
Univariate
Multivariate
Univariate
≤250
1.07(0.87-1.32)
1.23(0.16-8.09)
0.551
In-hospital Mortality
>250
1.45(1.09-1.92)
1.32(1.02-1.72)
0.015
≤250
1.02(0.89-1.18)
1.09(0.90-1.32)
0.79
28-day Mortality
>250
1.2(0.96-1.5)
1.31(1.01-1.71)
0.13
≤250
1.03(0.97-1.06)
0.93(0.85-1.02)
0.19
Length of Hospital Stay
>250
0.89(0.78-1.02)
0.97(0.84-1.11)
0.19
≤250
0.99(0.91-1.07)
0.95(0.87-1.05)
0.83
Time to Clinical Stability
>250
1.03(0.91-1.18)
1.13(0.98-1.31)
0.83
Notes: (a) The confounders in this study includes variables like in-hospital mortality:
PaO2 <60 mmHg, ICU admission or transfer, Hematocrit <30%, BUN ≥30mg/dl, Systolic BP<90mmHg,
pH<7.35, respiratory rate >30 breaths/min, Multilobar infiltrates on chest xray. Prior influenza vaccination
Outcome

Multivariate
0.237
0.034
0.398
0.048
0.130
0.630
0.320
0.086

(b) Reference group is non-DM patients with blood glucose level ≤ 250 mg/dl (control group)

no significant increase in TCS (HR = 1.13, 95% CI: 0.98-1.13, p
= 0.086) and LOS was found (HR = 0.97, 95% CI: 0.84-1.11, p
= 0.630). Patients in the DM BG ≤ 250 mg/dL group compared
to the control group did not have a statistically significant greater
risk for in-hospital mortality (RR = 1.23, 95%: 0.16-8.09, p =
0.237), 28-day mortality (RR = 1.09, 95% CI: 0.90-1.32, p =
0.398), LOS (HR = 0.93, 95% CI: 0.85-1.02, p = 0.130), or TCS
(HR = 0.95, 95% CI: 0.87-1.05, p = 0.320).

4

Discussion

Our study reveals that patients with DM and BG > 250 mg/dL
had a higher in-hospital mortality and 28-day mortality compared to those in the control group, whereas those with DM and
BG < 250 mg/dL did not appear to adversely affect any clinical
outcomes compared to the control group. There was no significant difference among the three groups when comparing TCS
and LOS. These four outcomes were measured after adjusting for
confounders in the multiple Cox regression and multiple logistic
regression analysis. The higher mortality of CAP found in pa26 |
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tients with DM and BG > 250mg in the present study is consistent with prior investigations. Previous studies generally showed
the association between hyperglycemia and higher mortality 8,9 ,
but the effects of well-controlled or pre-existing diabetes on clinical outcomes in patients with CAP have not been well studied.
One contributing factor to the aforementioned inconsistencies is
the lack of a clear definition of uncontrolled and controlled DM;
which have been based on plasma glucose measures upon hospital admission. A recent multicenter prospective cohort examined
DM patients admitted with CAP from 2003 to 2009 8 . This study
showed mild hyperglycemia (108-198 mg/dL) at hospital admission to be associated with risk of death at 90 days (RR=1.56, 95%
CI: 1.22-2.01, P<0.001) and higher risk of death in those with
severe hyperglycemia (blood glucose > 252 mg/dL) (HR=2.37,
95% CI: 1.62 to 3.46, P > 0.001) 8 .
Our study association of BG > 250 mg/dL with high mortality
of patients with CAP could be analyzed in two ways. One way
is whether BG < 250 mg/dL is a predictor of poor outcome or

whether it is an effect of severity of CAP, leading to poor clinical outcomes. Robinson et al. have demonstrated that any acute
illness can cause hyperglycemia due to combination of multiple
metabolic effects including raised glucocorticoid hormone concentrations, elevated plasma catecholamine levels and increased
peripheral insulin resistance 14 . Multiple hypotheses have been
proposed to evaluate how hyperglycemia can cause adverse effect in acute illness. Van de Berghe et al have proposed that hyperglycemia causes cellular glucose overload and oxidative stress
increasing the superoxide and peroxynitrate production; which
may cause mitochondrial toxicity. This may eventually lead to
organ and tissue dysfunction contributing to death 15 . Glucose
in airway secretions could predispose to respiratory infection by
promoting bacterial growth or interfering with local innate immunity 16 .
However, unlike the present study, patients with pre-existing DM
had a higher risk of mortality (RR = 2.47 95% CI: 2.05 to 2.98,
p = < 0.001) regardless of blood glucose levels upon admission.
A retrospective analysis of two multicenter cohorts showed an increase in 1-year mortality in the Gen IMS cohort for pre-existing
DM (unadjusted RR = 1.41, 95% CI: 1.12-1.76, p = 0.002), this
increase in mortality persisted after adjustment for cardiovascular and renal disease (HR= 1.3, CI: 1.03-1.65) 7 . However, in the
Health ABC cohort, the association between pre-existing diabetes
and 1-year mortality was not found to be significant (1.87, 95%
CI: 0.76-4.6, p = 0.16) 7 . A Danish population based cohort study
found increased 30-day (MRR = 1.16, 95% CI: 1.07-1.27) and
90-day (MRR = 1.10, 95% CI: 1.02-1.18) mortality among those
with DM compared to those without DM however both mortality
risk diminished after adjustment for hyperglycemia upon admission 6 . Conversely, a Canadian population based prospective cohort study found no significant association between blood glucose
levels on admission and 90-day mortality after adjusting for functional status and PSI score (RR = 1.30, 95% CI: 0.88-1.93) for
those in the 11.1-20 mmol/l group) 10 . Our study has strengths
and limitations. The main limitation is that this study was not
specifically designed to evaluate outcomes of CAP in diabetic patients. The CAPO database is designed to track multiple factors
associated with CAP outcomes with the limitation of assessing BG
> 250 mg/dL as the only BG level. Despite this shortcoming, this
series of 1294 diabetic patients is adequately powered to evaluate the association between these 2 conditions. There was no
documentation how aggressive the blood glucose was controlled
during patient hospital course and this could have impacted the
outcomes. Lack of hemoglobin A1C documentation is a weakness
of our study to evaluate the retrospect control of DM among our
patients. Also this is a retrospective, non-consecutive study and
there was no stratification for treatments. One of the strengths of
the study is the large patient population included in the study. We
conclude that it is the presence of DM with BG > 250 mg/dL that
contributes to increased in-hospital mortality and 28-day mortality. This implies that the mere presence of Diabetes mellitus does
not contribute to the increase in In-hospital mortality, 28 days
mortality, length of stay and time to clinical stability. It is the presence of hyperglycemia in Diabetic population that contributes to

the poor outcome. This emphasizes on the fact that more efforts
are needed to increase awareness of impact of hyperglycemia in
DM on the clinical outcomes of CAP. These results indicate the
importance of keeping the blood glucose of CAP patients under
control. In addition, further studies are needed to link the role of
hyperglycemia to CAP outcome to better understand this association.
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